Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
pharmaphorum29m
Ouro makes debut with $120m for autoimmune disease TCEs
Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...
manilatimes1h
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
FierceBiotech1h
Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO
Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...
Ouro Medicines Launches To Define The Future Of Treatment For People With Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
FierceBiotech4h
GSK-backed Ouro Medicines launches into T-cell engager space with $115M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
PharmiWeb5h
Biogen Appoints Adam Feire as Head of Business Development and External Innovation
Biogen Inc. (Nasdaq: BIIB) – today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice ...
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...